Brodalumab
Brodalumab
Brodalumab (pronounced broh-dah-LOO-mab) is a human monoclonal antibody used for the treatment of psoriasis, a chronic skin condition. It is marketed under the brand name Siliq in the United States and Kyntheum in Europe.
Etymology
The name "Brodalumab" is derived from the combination of the words "broad" and "lumab", where "lumab" is a common suffix for monoclonal antibodies. The "broad" part of the name is likely a reference to the broad spectrum of inflammatory conditions that the drug can potentially treat.
Mechanism of Action
Brodalumab works by binding to the interleukin-17 receptor A (IL-17RA), a protein that plays a key role in the development of psoriasis. By blocking this receptor, Brodalumab can reduce the inflammation and other symptoms associated with psoriasis.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Psoriasis: A chronic skin condition that causes cells to build up rapidly on the surface of the skin.
- Interleukin-17 receptor A: A protein that plays a key role in the development of psoriasis.
See Also
External links
- Medical encyclopedia article on Brodalumab
- Wikipedia's article - Brodalumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski